Skip to main content
Journal of Applied Physiology logoLink to Journal of Applied Physiology
. 2015 Apr 30;119(10):1164–1172. doi: 10.1152/japplphysiol.00283.2015

Metabolic reprogramming and inflammation act in concert to control vascular remodeling in hypoxic pulmonary hypertension

Kurt R Stenmark 1,3,, Rubin M Tuder 4, Karim C El Kasmi 2
PMCID: PMC4816410  PMID: 25930027

Abstract

Pulmonary hypertension (PH) is a complex, multifactorial syndrome that remains poorly understood despite decades of research. PH is characterized by profound pulmonary artery (PA) remodeling that includes significant fibro-proliferative and inflammatory changes of the PA adventitia. In line with the emerging concept that PH shares key features with cancer, recent work centers on the idea that PH results from a multistep process driven by reprogramming of gene-expression patterns that govern changes in cell metabolism, inflammation, and proliferation. Data demonstrate that in addition to PA endothelial cells and smooth muscle cells, adventitial fibroblasts from animals with experimental hypoxic PH and from humans with PH (hereafter, termed PH-Fibs) exhibit proinflammatory activation, increased proliferation, and apoptosis resistance, all in the context of metabolic reprogramming to aerobic glycolysis. PH-Fibs can also recruit, retain, and activate naïve macrophages (Mϕ) toward a proinflammatory/proremodeling phenotype through secretion of chemokines, cytokines, and glycolytic metabolites, among which IL-6 and lactate play key roles. Furthermore, these fibroblast-activated Mϕ (hereafter, termed FAMϕ) exhibit aerobic glycolysis together with high expression of arginase 1, Vegfa, and I1lb, all of which require hypoxia-inducible factor 1α and STAT3 signaling. Strikingly, in situ, the adventitial Mϕ phenotype in the remodeled PA closely resembles the Mϕ phenotype induced by fibroblasts in vitro (FAMϕ), suggesting that FAMϕ crosstalk involving metabolic and inflammatory signals is a critical, pathogenetic component of vascular remodeling. This review discusses metabolic and inflammatory changes in fibroblasts and Mϕ in PH with the goal of raising ideas about new interventions to abrogate remodeling in hypoxic forms of PH.

Keywords: glycolysis, HIF, IL-6, fibroblast, macrophage


people with pulmonary hypertension (PH), due to lung diseases and/or hypoxemia, comprise a distinct group (Group 3) in the World Health Organization (WHO) clinical classification system (80). WHO Group 3 comprises a heterogeneous set of diseases sharing the common feature of hypoxia-induced pulmonary vascular remodeling. The presence of PH in these patients, who include survivors of acute lung injury and those with pulmonary fibrosis or chronic obstructive pulmonary disease (COPD), significantly worsens morbidity and mortality. Furthermore, recent data demonstrate that in these patients, PH is markedly underdiagnosed and is specifically associated with substantial mortality (19, 45, 53). Unfortunately, all therapies currently approved for use in PH have been designed for patients with WHO Group 1 PH [so-called pulmonary arterial hypertension (PAH), e.g., idiopathic PAH (iPAH), scleroderma PAH, human immunodeficiency virus-related PAH, etc.], and to date, no clinical trial with these drugs has shown benefit in patients with WHO Group 3 disease (78). Furthermore, whereas oxygen supplementation attenuates PH and improves overall survival in patients with COPD, it remains unclear whether these effects are mediated by improved pulmonary vascular modeling or why some patients with COPD develop severe pulmonary vascular disease despite oxygen therapy (1, 10). Thus the identification of underlying pathogenic mechanisms, which may instruct the development of novel and improved treatment strategies for PH in these patients, is of paramount importance. The goal of this mini-review is to examine evidence supporting the hypothesis that chronic hypoxia can induce adaptations in metabolism of both mesenchymal cells (specifically fibroblasts) and immune cells [macrophages (Mϕ)], particularly in genetically susceptible individuals, who induce and maintain signaling networks that drive sustained increases in cell proliferation and inflammatory activation/phenotype (Fig. 1). This cell-proliferation/inflammation nexus is therefore critical to the pathogenesis of PH.

Fig. 1.

Fig. 1.

In line with the emerging concept that pulmonary hypertension (PH) shares key features with cancer, increasing evidence supports the idea that PH results from a multistep process driven by reprogramming genes that govern changes in cell metabolism, inflammation, and proliferation. Pulmonary artery adventitial fibroblasts from animals with experimental hypoxic PH and from humans with pulmonary arterial hypertension exhibit proinflammatory activation, increased proliferation, and apoptosis resistance, all in the context of metabolic reprogramming to aerobic glycolysis. These activated adventitial fibroblasts can recruit, retain, and activate macrophages (Mϕ) toward a distinct proinflammatory/proremodeling phenotype through the secretion of chemokines, cytokines, and other metabolites, including lactate. This fibroblast-activated Mϕ (FAMϕ) also exhibits a switch to aerobic glycolysis, which is regulated through a STAT3-hypoxia-inducible factor 1 (HIF1) signaling axis. Collectively, this fibroblast-FAMϕ signaling unit plays a critical role in the persistent inflammation and fibrosis that characterize certain forms of PH. HDAC, histone deacetylase; miR-124, microRNA 124; PTBP1, polypyrimidine tract-binding protein 1; TCA, tricarboxylic acid; PKM2, M2 isoform of pyruvate kinase; Glut1, glucose importer typically up-regulated in cells adapted to high glycolysis; PH-Fib, adventitial fibroblasts from animals with experimental hypoxic PH and from humans with PH; PTEN, phosphatase and tensin homolog; MCP1, monocyte chemoattractant protein 1; pSTAT3, phosphorylated STAT3; Arg1, arginine 1; TGFβ, transforming growth factor β.

METABOLIC THEORY OF PH: RELATIONSHIP TO CANCER

Lung tissue hypoxia, to a variable extent, is common to all of the conditions encountered in patients with Group 3 PH. As the lung cells, including the pulmonary vasculature, react to hypoxia, PH develops; this paradigm is particularly relevant in patients with COPD, sleep-disordered breathing, and fibrosing interstitial lung diseases and those living in altitude (80, 83). Oxygen therapy alone, in these patients, is usually not sufficient to normalize pulmonary arterial pressure, suggesting the involvement of cellular growth mechanisms, which cannot wholly be explained by hypoxic vasoconstriction responses (45). Importantly, in all of these conditions, PH is also consistently associated with early and persistent perivascular inflammation and pulmonary arterial remodeling (87, 93). A striking feature is the predominance of perivascular Mϕ surrounding remodeled pulmonary arteries (27, 49, 77). This remodeling involves an imbalance of cell proliferation vs. cell death, which taken in conjunction with inflammation and Mϕ activation, has led to the hypothesis that the cellular and molecular features of PH resemble hallmark characteristics of cancer monoclonal behavior (18, 39, 93, 95). It is increasingly recognized that changes in cell metabolism in cancer cells, as well as in cells in the surrounding stroma, including Mϕ, are essential for cancer cells to proliferate, migrate, and exhibit proinflammatory characteristics (22, 55, 101). As such, there is an intense effort in the cancer field to define the molecular mechanisms that underlie the coordinated response of cancer cells with their immediate cellular microenvironment, made of cancer-associated fibroblasts (CAFs) and Mϕ. The basis of this interaction relates to changes in metabolism, growth, and inflammation. These pathogenic nodes may offer new opportunities for therapy.

Strikingly, a metabolic adaptation akin to aerobic glycolysis (“Warburg-like”), historically assigned to cancer cells, has also recently been reported in PH (18, 32, 67, 93, 105). These changes have been described to occur in smooth muscle cells (SMCs), endothelial cells, and fibroblasts (34, 67). Additional strong data in support of the importance of this metabolic adaptation are supported by 18-fluorodeoxyglucose (18FDG) PET imaging, which has demonstrated increased glucose uptake and metabolism in PAH patients as well as in the monocrotaline rat model of PH (54, 105). Furthermore, 18FDG uptake and gene-expression studies in pulmonary arterial fibroblasts, isolated from iPAH patients, lend support to the concept that a proliferative and inflammatory pulmonary vascular pathology contributes to the lung 18FDG PET signal (105). This study also showed that 18FDG uptake occurs in perivascular mononuclear cells, which accumulate in the adventitial perivascular regions. In vivo studies in the monocrotaline model demonstrated a close correlation between lung 18FDG uptake and pulmonary vascular remodeling. Importantly, enhancement of oxidative glycolysis with dichloroacetate-mediated inhibition of the enzyme pyruvate dehydrogenase kinase attenuated PH and vascular remodeling in this model and also reduced expression of the glucose transporter (Glut1) typically upregulated in cells exhibiting high glycolysis. These findings correlated with reduced 18FDG PET signals, which were associated with decreased peripheral vascular muscularization and inflammatory cell accumulation. Collectively, these in vivo and ex vivo observations support a “metabolic hypothesis” for the pathogenesis of PH, whereby a rearrangement of the mitochondrial and cytosolic metabolism, known as the “Warburg effect,” might explain, at least partially, the molecular and functional abnormalities seen in PH cells, including excessive proliferation, apoptosis resistance, and inflammatory activation (67).

METABOLIC AND INFLAMMATORY CHANGES IN FIBROBLASTS AND Mϕ IN CANCER

Our laboratory has been particularly focused on fibroblasts and Mϕ in PH, based on observations of inflammation occurring largely in the perivascular regions in PH (which harbor fibroblasts and Mϕ) in humans and animal models of PH (9, 77, 85, 87). Interestingly, similar observations of largely adventitial inflammatory responses, mostly involving Mϕ, are observed in systemic circulation in response to changes in blood flow and are necessary for remodeling (89). It seems that despite marked cytokine and chemokine production by medial SMCs, Mϕ accumulation occurs largely in the adventitia (48, 108). These observations are consistent with the idea that under most circumstances, the vascular media of almost all arteries appear to be an immune-privileged site (91). Here again, the cancer paradigm is appropriate: consistent with the hypothesis put forth by Dvorak (26), almost 30 years ago—that a “tumor is a wound that never heals”—an ever-increasing body of evidence demonstrates that the fibroblasts and Mϕ in tumors, often referred to as CAFs and tumor-associated Mϕ (TAMs), are key players in the process of tumorigenesis (39, 62). Several recent studies have shown that in many cancers, the cancer-promoting and therapy-resistant properties of the tumor stroma largely reside in the activity of fibroblasts and Mϕ (61, 62). CAFs have been shown to play roles in many aspects of tumor initiation, progression, and metastasis. CAFs are now implicated in the following: 1) modulating the tumor and microenvironment through the secretion of a large variety of soluble factors; 2) modifying tumor metabolism; 3) remodeling the extracellular matrix of the tumor; 4) regulating cancer stemness; 5) modulating the immune response (and affecting Mϕ phenotype); 6) promoting cancer cell migration and metastasis; and 7) altering therapeutic responses in a variety of tumors (12, 13). Of particular relevance to the hypothesis that PH exhibits a critical relationship to cancer is the ability of fibroblasts to secrete cytokines and growth factors, their ability to modify tumor metabolism, and their role in modulating immune responses and Mϕ phenotype. A wide variety of growth factors and cytokines has been documented to be produced and released into the tumor microenvironment by fibroblasts (75). The CAF secretome also regulates angiogenesis. VEGF-A as well as CXCL12, CXCL14, and connective tissue growth factor are induced in CAFs by neoplastic cells (4). Interestingly, CAFs also show important metabolic changes that probably promote their own survival as well as promote tumorigenesis. CAFs demonstrate increased autophagy in concert with upregulation of members of the glycolytic pathway, including phosphoglycerate kinase 1 (PGK1). Overexpression of PGK1 in normal fibroblasts results in a myofibroblastic phenotype and an ability to promote tumor cell growth (13, 99). Furthermore, in many tumors, CAFs express glycolytic enzymes related to the Warburg effect, such as the M2 isoform of pyruvate kinase (PKM2), as well as lactate dehydrogenase. This metabolic adaptation toward increased aerobic glycolysis in CAFs is hypothesized to generate lactate and ketones, which are secreted into the intracellular space and can act as paracrine oncometabolites that fuel the oxidative mitochondrial metabolism in neoplastic cells. This phenomenon is often referred to as the “reverse” Warburg effect (68). In addition, lactate and ketones have been recognized to modulate Mϕ activation (16).

As noted, chronic inflammation is a prominent risk factor for many cancers. An inflammatory environment, especially in the context of the metabolic environment described above, is known to promote error-prone, high-rate proliferation, thereby facilitating tumorigenesis (37). CAFs mediate tumor-enhancing inflammation by expressing a proinflammatory gene signature, which creates a microenvironment that attracts myeloid cells and supports tumor growth and angiogenesis (92). Importantly, carcinoma cells can induce normal surrounding fibroblasts to turn on a proinflammatory gene signature. Furthermore, accumulating evidence shows that the tumor stroma and CAFs, in particular, actively participate in modulating the immune response to help neoplastic cells escape detection, thereby supporting tumor progression (43). Recent studies have shown that depletion of fibroblast-activating protein α-positive cells restored immunologic detection and destruction of the tumor, indicating that presumably fibroblasts can act as immunosuppressant cells in the tumor microenvironment (31). Additionally, reports suggest that at least within the pancreas, fibroblast-like cells induce the differentiation of peripheral blood mononuclear cells into immune-suppressive, myeloid-derived suppressor cells, contributing to T cell inhibition (51). In summary, CAFs possess the ability to manipulate the innate (i.e., Mϕ, natural killer cells) and the adaptive immune system (i.e., T cells) to maintain an aberrant inflammatory environment tailored to promoting tumorigenesis.

METABOLIC AND INFLAMMATORY CHANGES IN PULMONARY ARTERIAL ADVENTITIAL FIBROBLASTS: PARALLELS TO CAFs

Fibroblasts are also recognized to play a critical role within the vasculature and its innate immune system in the absence of oncogenic transformation by acting as “sentinel” cells (8, 25, 44, 79, 86, 87), which detect and respond to a variety of local environmental stresses and thereby initiate and coordinate pathophysiological responses (5, 6, 8, 33, 41, 63, 81, 82, 96, 102). We have documented that in both experimental hypoxic PH and human PAH, the pulmonary artery (PA) adventitia harbors activated fibroblasts (hereafter, termed PH-Fibs) with a hyperproliferative, apoptosis-resistant, and proinflammatory phenotype that persists ex vivo over numerous passages in culture (2, 20, 49, 66, 98). This particular phenotype would be centrally involved in cell signaling, shaping the surrounding inflammation-prone microenvironment. Indeed, in line with the cancer paradigm—that stromal cells play a critical role in initiation and perpetuation of inflammation (7, 40, 81, 84, 86, 87, 96, 102)—we have recently shown that PH-Fibs potently recruit, retain, and activate naïve Mϕ (27, 49). Bovine PH-Fibs exhibit an intriguingly similar cytokine profile to that described for CAFs. We have recently established that these fibroblast-activated Mϕ (FAMϕ) are polarized to a very distinct, heretofore undescribed, proinflammatory/proremodeling phenotype, in which STAT3 and hypoxia-inducible factor 1α (HIF1α) signaling promote expression of genes implicated in chronic, nonresolving tissue responses in PH [e.g., Pim1; nuclear factor of activated T cells, cytoplasmic 2; Arginase-1 (Arg1); VEGF] (27). This fibroblast-driven polarization of Mϕ into a distinct phenotype is similar to that recently described for hypoxic tumor-driven Mϕ polarization (16, 51). In addition, expression of Arg1, Hif1, and Vegfa is characteristic of wound-healing Mϕ (26, 58). Thus Mϕ activation and expression of HIF1α, Arg1, and Vegfa appear to not only be a functional requirement for Mϕ to promote physiological wound healing but also can be “high jacked” to shape an environment, not only conducive to tumor growth but also importantly, to promote pathological tissue remodeling. These observations highlight the idea that hypoxia signaling, inflammation, and remodeling and ultimately, PH are linked through stromal cell (fibroblast)/Mϕ interactions, driven specifically by local changes in a hypoxic or hypoxic-like vascular microenvironment.

Data also show that similar to cancer cells, which reprogram metabolic pathways to support high proliferation (Warburg effect) (3, 23, 24, 57, 71, 88, 93), highly proliferative PH-Fibs exhibit a marked and persistent change in their metabolism toward aerobic glycolysis (i.e., Warburg effect), which is maintained ex vivo (105). However, the mechanisms controlling the metabolic, molecular, and functional changes in the fibroblast phenotype in PH have only recently begun to be investigated. Importantly, observations from our laboratory (49, 66, 87, 93, 95, 98, 106) have documented that cells (including SMCs, endothelial cells, and fibroblasts), derived from the PH vessel wall, exhibit durable ex vivo changes in their metabolic state (aerobic glycolysis), as well as in their proliferative and inflammatory capabilities and in their “molecular phenotype”. Stable, “imprinted” changes in the functional phenotype of cell observations strongly support the idea that these stable changes in cells, especially as they relate to metabolism and cell signaling, could arise from acquired somatic mutations and/or epigenetic change.

Here again, there is a striking parallel to observations in cancer. It is now well accepted that signal transduction regulates metabolism (101). Cancer cells exploit signaling-dependent regulation of metabolism. For example, oncogenic activation of signal transduction pathways drives nutrient uptake and metabolism to support continuous macromolecular biosynthesis and cell proliferation (46, 101). Reciprocally, signaling pathways have been shown to be regulated by metabolism through intracellular nutrient-sensing molecules, such as AMP-activated protein kinase (AMPK) and mammalian target of rapamycin complex 1. In addition, metabolites may serve as indicators of the metabolic status of the cell and through metabolite-sensitive protein modifications, modulate the activity of signaling proteins, metabolic enzymes, and transcriptional regulators (101). Modifications, including acetylation, methylation, glycosylation, and phosphorylation, are all generated from metabolites (56). Acetylation, a protein modification involving the addition of an acetyl group obtained from the metabolite acetyl-CoA, is controlled by the combined activities of acetyltransferases and deacetylases (38). There is evidence that both acetylation and deacetylation can be influenced by nutrient availability, suggesting that protein acetylation could serve as a sensitive indicator of cellular metabolic resources (101). It is also recognized that metabolism itself can be regulated by acetylation. A growing body of evidence indicates that nearly all enzymes involved in glucose and fatty acid metabolism are acetylated (107). For some of these enzymes, such as the critically important PKM2, acetylation seems to modulate their activity in a nutrient-responsive, biologically meaningful way (15, 50, 107). The acetylation status of PKM2 was shown to be relevant to tumor growth, as expression of an acetylation mimetic mutant version of PKM2 enhanced the growth of xenograft tumors (50).

Similarities to this concept of reciprocal regulation of metabolism and signaling have been raised in PH. We recently documented that the highly proliferative, apoptotic-resistant, and proinflammatory [high expression of IL-6, CCL2/monocyte chemoattractant protein 1 (MCP-1), CCL12/stromal cell-derived factor 1, IL-1β] phenotype of PH-Fibs, isolated from the pulmonary circulation of humans and calves with severe PH, is mediated, at least in part, by a marked decrease in the expression of microRNA 124 (miR-124) and the increased expression of its direct target, the alternative splicing factor polypyrimidine tract-binding protein 1 (PTBP1), as well as increased expression of class I histone deacetylases (HDACs), a specific subgroup of the deacetylase mentioned above (98). With the use of miR-124 inhibitors and mimics in human and bovine fibroblasts, we demonstrated that overexpression of miR-124 decreased the proliferation and migration rates of PH-Fibs. Similarly, inhibition of miR-124 (via anti-miR-124) in normal control fibroblasts (CO-Fibs) augmented cell proliferation and migration, demonstrating that miR-124 regulates proliferative and migratory characteristics of fibroblasts. It should be noted that with the use of both miR array analysis and real-time PCR, we noted decreased expression of several other miRs (including miR-184; miR-21, miR-155) in PH-Fibs (from calves and humans) compared with corresponding controls. We made miR mimics of each of these miRs and transfected them into PH-Fibs, as we did for miR-124. In no case did overexpression of these miRs decrease proliferation, migration, or inflammatory cytokine expression. Collectively, these data suggest that loss of miR-124 in PH-Fibs is a major contributor to their “constitutively” activated phenotype.

To elucidate the mechanisms by which miR-124 regulates cell proliferation and migration, we screened transcript levels of cell cycle-related genes and found that miR-124 positively regulates Notch1, phosphatase and tensin homolog (PTEN), forkhead box O3 (FOXO3), p21/Cip1, and p27/Kip1, all of which were reduced in PH-Fibs. Next, we sought to determine the target of miR-124 upstream of the cell cycle regulator genes, knowing that these genes would have to increase, since miR-124 was decreased, as it suppresses cell cycle genes. Previously published data identified PTBP1 as a direct target of miR-124 and showed that PTBP1 can suppress Notch1 signaling (14, 52). Therefore, we focused on PTBP1, which is an abundantly expressed RNA-binding protein involved in several post-transcriptional regulation events, including repression of RNA alternative-splicing events, activation of internal ribosomal entry site-driven translation, and RNA localization and stability. It is overexpressed in a variety of cancer cells in response to oncogenes, such as cMyC and the transcription factor STAT3. We found that PTBP1 expression is increased in bovine and human PH-Fibs (in vitro), as well as in vivo in PA adventitia of humans and calves with severe PH (98). Overexpression of miR-124 (using miR-124 mimics) in human and bovine PH-Fibs inhibited PTPB1 expression, whereas inhibition of miR-124 (using anti-miR-124) in CO-Fibs upregulated PTBP1 expression. We conducted luciferase/PTPB1 3′ untranslated region assays and proved that PTBP1 is a direct target of miR-124 (98). We also showed that PTBP1 acts upstream of Notch1 and negatively regulates the cell cycle-related genes Notch1, PTEN, FOXO3, p21, and p27. Importantly, it is also known that PTBP1 controls splicing of pyruvate kinase, and its increased expression leads to overexpression of the PKM2 isoform, which as noted above, is an important regulator of the metabolic state of cells. These novel findings demonstrate that miR-124 expression is markedly attenuated in PH-Fibs and results in an increase of an RNA-binding protein, PTBP1, which post-transcriptionally regulates expression of several genes controlling cell proliferation, metabolism, and inflammation.

Given the importance of PTBP1 in regulating the proliferative, metabolic, and inflammatory phenotype of PH-Fibs, we performed experiments elucidating the mechanism controlling expression of miR-124. Since it has previously been shown that miR-124 itself is subject to epigenetic modifications (36, 100), we interrogated whether miR-124 is epigenetically silenced in PH-Fibs. Perhaps not unexpectedly, given the significant change in metabolic status of PH cells (aerobic glycolysis) and the increase in class I HDAC expression, we found that treatment of PH-Fibs with the HDAC inhibitors, suberoylanilide hydroxamic acid and Apidicin, led to a significant increase in miR-124 expression with concurrent decreases in expression of its direct targets, PTBP1 and CCL2/MCP-1 (98). These observations support our previously published data, showing increased class I HDAC activity in cultured PH-Fibs and in hypoxic lungs (11, 106). Furthermore, this suggested that decreased miR-124 expression in PH-Fibs occurred through epigenetic modifications, likely through the removal of acetylation marks on histones, resulting in a more condensed chromatin structure and inhibition of transcription. Such an epigenetic event would explain the constitutively activated phenotype of PH-Fibs, which we have shown to be “reversible” (close to normal) through the application of HDAC inhibitors (11, 106).

In summary, it seems increasingly clear that a fibroblast (fibroblast-like cell) emerges in the adventitia of humans and animals with severe PH that bears a striking resemblance to CAFs. These cells exhibit a Warburg-like glycolytic phenotype and are characterized by excessive proliferation, apoptosis resistance, and a proinflammatory phenotype. Metabolism and signaling pathways in these cells are intimately linked and driven by epigenetic changes that are intimately linked to the metabolic state of the cell (Fig. 1).

METABOLIC AND INFLAMMATORY CHANGES IN PA FAMϕ

We propose that the synchronized and mutually interactive signaling between pulmonary perivascular fibroblasts and Mϕ is central in PH pulmonary vascular remodeling. There is evidence that Mϕ accumulation in the remodeled PA is largely restricted to the adventitia, where Mϕ are in close proximity to adventitial fibroblasts and that Mϕ critically contribute to the vascular remodeling process (27, 35, 73, 77, 86). Importantly, there is evidence for adventitial Mϕ progenitor cells (at least in the systemic circulation in the setting of atherosclerosis) that can serve as a durable pool for adventitial Mϕ populations (72). As outlined for fibroblasts above, rapidly increasing evidence supports a role for the Warburg effect in immune activation (65), specifically, in Mϕ and dendritic cells (DCs). Initial reports by the Pearce lab (29, 30, 47, 69) have demonstrated that Toll-like receptor-activated DCs undergo a metabolic adaptation from oxidative phosphorylation to aerobic glycolysis and that this metabolic switch is critical for DC maturation and function, while it also regenerates NADP oxidase and citric acid cycle intermediates to support fatty acid production. In DCs, this metabolic switch to aerobic glycolysis is promoted by phosphatidylinositol 3 kinase/Akt signaling and is inhibited by the AMPK, a central regulator of catabolic metabolism that is also displayed by cancer cells (29). More recent reports by the O'Neill lab (64, 90) have similarly shown that increased aerobic glycolysis and reduced oxidative phosphorylation are critical events required for innate Mϕ activation in response to LPS. These studies have also identified PKM2 as the critical molecular switch to turn on aerobic glycolysis in LPS-activated Mϕ (64). Conversely, the alternatively activated Mϕ phenotype (induced by IL-4) depends on increased oxidative phosphorylation and lipolysis (42, 60, 76, 97). It is, however, unresolved which metabolic adaptations occur in and are critical for the functional phenotype of Mϕ associated with chronic tissue remodeling and fibrosis, especially because these Mϕ often resist categorization into the extremes of M1 (LPS-activated) vs. M2 (IL-4-activated) phenotypes (27); their functional phenotype may be in flux, changing due to local environmental signaling and metabolic conditions. In addition, in chronic tissue-remodeling conditions, there may be absence of IFN-γ and/or LPS (the M1-defining stimuli) and IL-4/IL-13 (the M2-defining stimuli) but presence of tissue-derived danger signals and cytokines, such as IL-6 (27), which drive Mϕ activation toward displaying a considerable overlap between M1 and M2 phenotypic gene-expression markers and thus Mϕ function (27); conceivably, these Mϕ, including FAMϕ, in vascular remodeling associated with PH, may therefore exhibit metabolic features overlapping with those typically observed in and defining the M1 (LPS-activated) and M2 (IL-4-activated) Mϕ phenotypes. Whereas they express HIF1 and features of increased aerobic glycolysis, they also express increased mRNA and protein for Arg1. Importantly, this fibroblast-activated phenotype is critically dependent on STAT3 signaling, which clearly and distinctly differentiates it from M1 and M2 (27).

The major consequence of metabolic adaptation toward aerobic glycolysis in LPS-activated Mϕ is generation of increased concentrations of the citric acid cycle intermediate succinate (90), which is a potent prolyl hydroxylase (PHD) inhibitor and thus stabilizer of HIF1. The functional consequence of this LPS-mediated HIF1 stabilization through metabolic reprogramming in Mϕ is increased transcriptional activation of the proinflammatory gene Il1b. In addition, in LPS-activated Mϕ, increased activity of PKM2 further promotes HIF1-mediated transcriptional induction of IL-1β and other cytokines in colorectal cancer cells (104). PKM2 is also critical for enhancing STAT3 signaling (through increased phosphorylation) (21, 103, 104), whereas STAT3, in turn, increases HIF1 signaling and expression of Glut1, which is important for glucose uptake and maintenance of increased glycolysis, enhancing the anaerobic metabolism (Warburg effect). Thus this PKM2-STAT3-HIF feedforward may be a critical signaling pathway in tissue Mϕ associated with areas of remodeling and fibrosis that typically lack strong M1-inducing signals and is not associated with IL-4 and canonical M2 Mϕ but instead, exhibits STAT3 and HIF1 signaling (27, 104). Moreover, PKM2 can drive expression of Arg1 through activation of STAT3, which as we have reported, is highly upregulated in FAMϕ (27). Increased activity of Arg1 through metabolism of arginine can have profound effects on restricting arginine availability to “client cells” (e.g., adventitial fibroblasts) (70). Under arginine-limiting conditions, Mϕ initiate a salvage pathway (74) that consumes aspartate and generates fumarate, thus directly affecting concentrations of citric acid cycle intermediates that are capable of inhibiting PHDs and thus stabilizing HIF1. Moreover, increased aerobic glycolysis produces increased amounts of lactate. Importantly, because FAMϕ does display evidence of both aerobic glycolysis and citric acid cycle activity (unpublished observations), akin to activated T cells (59), pyruvate is excreted as lactate but also entered into the citric acid cycle; in this regard, lactate has been shown to be a potent activator of Mϕ toward expression of HIF1 and Arg1 (16). Together, these metabolic pathways make these cells glutamine-dependent, whereas the arginine metabolism through Arg1 may provide glutamate and help replenish the citric acid cycle (unpublished observations).

As such, activation of STAT3, HIF1, and PKM2 in the molecular crosstalk between Mϕ and fibroblasts through bidirectional generation and consumption of metabolites downstream and upstream of aerobic glycolysis may perpetuate rather than attenuate inflammatory activation (Fig. 1).

Intriguingly, inhibition of this PKM2 activity has been shown to convert the LPS-activated phenotype toward a Mϕ with anti-inflammatory features, as indicated by increased expression of IL-10 (64). Interestingly, in DCs, IL-10 antagonizes DC maturation through inhibition of metabolic adaptation to aerobic glycolysis (47). Thus Mϕ phenotypic conversion toward generation of anti-inflammatory mediators and simultaneously increasing responsiveness of inflammatory Mϕ to anti-inflammatory IL-10 might be achieved by interfering with PKM2 activity. However, the ability of IL-10 to inhibit LPS-induced IL-1β transcription in Mϕ depends, to some degree, on Arg1, a PKM2-STAT3 target gene (unpublished observations). Precisely how PKM2, HIF1, and aerobic glycolysis affect IL-10 production and IL-10 responsiveness requires further analysis.

The aggregate of these findings demonstrates that functional Mϕ plasticity depends on discrete metabolic adaptions and suggests that Mϕ can be functionally re-educated through manipulating metabolism. However, whether a similar phenotypic conversion/re-education of Mϕ from proinflammatory to a less-inflammatory or even reparative Mϕ phenotype can be achieved by inhibition of HIF1 alone or by inhibition of aerobic glycolysis alone awaits further studies. Intriguingly, PKM2 might turn out to play a critical role as a “master regulator” in driving and/or fine-tuning Mϕ polarization and phenotypic reprogramming/re-education of Mϕ away from proinflammatory or proremodeling phenotypes, because it regulates HIF1 activity and glycolysis, and it also affects STAT3 phosphorylation and signaling (21).

In summary, CAFs and TAMs display considerable overlap with the phenotypes described for PH-Fibs and PH-Fib-activated Mϕ associated with vascular remodeling in PH. Therefore, similar molecular and metabolic mechanisms may govern fibroblast-Mϕ crosstalk in the process of tumorigenesis and vascular remodeling. PKM2 may prove to be a critical driver of the metabolic and functional crosstalk between CAFs and TAMs, as well as between PH-Fibs and FAMϕ. Thus PKM2 targeting may turn out to attenuate tumorigenesis and vascular remodeling through similar mechanisms. Interestingly, small molecule activators of PKM2 that enhance tetramerization activity have been shown to compromise the proglycolytic and pro-HIF signaling functions (64), and it is conceivable that these molecules also interfere with the ability of PKM2 to phosphorylate STAT3; they may thus prove to be potent inhibitors of the uncontrolled PKM2-STAT3-HIF feedforward signal but may also increase generation of and responsiveness to endogenous anti-inflammatory mediators, such as IL-10.

GRANTS

Support for this study was provided, in part, by the National Heart, Lung, and Blood Institute [Grants HL114887 (Axis), HL014985 (PPG), and HL125827 (R01)].

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

Author contributions: K.R.S. and K.C.E.K. conception and design of research; K.R.S. and K.C.E.K. prepared figures; K.R.S. and K.C.E.K. drafted manuscript; K.R.S., R.M.T., and K.C.E.K. edited and revised manuscript; K.R.S., R.M.T., and K.C.E.K. approved final version of manuscript.

REFERENCES

  • 1.Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 93: 391–398, 1980. [DOI] [PubMed] [Google Scholar]
  • 2.Anwar A, Li M, Frid MG, Kumar B, Gerasimovskaya EV, Riddle SR, McKeon BA, Thukaram R, Meyrick BO, Fini MA, Stenmark KR. Osteopontin is an endogenous modulator of the constitutively activated phenotype of pulmonary adventitial fibroblasts in hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 303: L1–L11, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Archer SL, Fang YH, Ryan JJ, Piao L. Metabolism and bioenergetics in the right ventricle and pulmonary vasculature in pulmonary hypertension. Pulm Circ 3: 144–152, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, Frederick MJ, Borg A, Micke P, Egevad L, Ostman A. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA 106: 3414–3419, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Baglole CJ, Ray DM, Bernstein SH, Feldon SE, Smith TJ, Sime PJ, Phipps RP. More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest 35: 297–325, 2006. [DOI] [PubMed] [Google Scholar]
  • 6.Barone F, Nayar S, Buckley CD. The role of non-hematopoietic stromal cells in the persistence of inflammation. Front Immunol 3: 416, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Barron L, Smith AM, El Kasmi KC, Qualls JE, Huang X, Cheever A, Borthwick LA, Wilson MS, Murray PJ, Wynn TA. Role of arginase 1 from myeloid cells in Th2-dominated lung inflammation. PloS One 8: e61961, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Buckley CD, Pilling D, Lord JM, Akbar AN, Scheel-Toellner D, Salmon M. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 22: 199–204, 2001. [DOI] [PubMed] [Google Scholar]
  • 9.Burke DL, Frid MG, Kunrath CL, Karoor V, Anwar A, Wagner BD, Strassheim D, Stenmark KR. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol 297: L238–L250, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Carlsen J, Hasseriis Andersen K, Boesgaard S, Iversen M, Steinbruchel D, Bogelund Andersen C. Pulmonary arterial lesions in explanted lungs after transplantation correlate with severity of pulmonary hypertension in chronic obstructive pulmonary disease. J Heart Lung Transplant 32: 347–354, 2013. [DOI] [PubMed] [Google Scholar]
  • 11.Cavasin MA, Demos-Davies K, Horn TR, Walker LA, Lemon DD, Birdsey N, Weiser-Evans MC, Harral J, Irwin DC, Anwar A, Yeager ME, Li M, Watson PA, Nemenoff RA, Buttrick PM, Stenmark KR, McKinsey TA. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism. Circ Res 110: 739–748, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 331: 1559–1564, 2011. [DOI] [PubMed] [Google Scholar]
  • 13.Chaudhri VK, Salzler GG, Dick SA, Buckman MS, Sordella R, Karoly ED, Mohney R, Stiles BM, Elemento O, Altorki NK, McGraw TE. Metabolic alterations in lung cancer-associated fibroblasts correlated with increased glycolytic metabolism of the tumor. Mol Cancer Res 11: 579–592, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Cheung HC, Corley LJ, Fuller GN, McCutcheon IE, Cote GJ. Polypyrimidine tract binding protein and Notch1 are independently re-expressed in glioma. Mod Pathol 19: 1034–1041, 2006. [DOI] [PubMed] [Google Scholar]
  • 15.Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, Fleming MD, Schreiber SL, Cantley LC. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452: 230–233, 2008. [DOI] [PubMed] [Google Scholar]
  • 16.Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM, Cline GW, Phillips AJ, Medzhitov R. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513: 559–563, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Cottrill KA, Chan SY. Metabolic dysfunction in pulmonary hypertension: the expanding relevance of the Warburg effect. Eur J Clin Invest 43: 855–865, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Cuttica MJ, Kalhan R, Shlobin OA, Ahmad S, Gladwin M, Machado RF, Barnett SD, Nathan SD. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 104: 1877–1882, 2010. [DOI] [PubMed] [Google Scholar]
  • 20.Das M, Burns N, Wilson SJ, Zawada WM, Stenmark KR. Hypoxia exposure induces the emergence of fibroblasts lacking replication repressor signals of PKCzeta in the pulmonary artery adventitia. Cardiovasc Res 78: 440–448, 2008. [DOI] [PubMed] [Google Scholar]
  • 21.Demaria M, Poli V. PKM2, STAT3 and HIF-1alpha: The Warburg's vicious circle. JAKSTAT 1: 194–196, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Doherty JR, Cleveland JL. Targeting lactate metabolism for cancer therapeutics. J Clin Invest 123: 3685–3692, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Dromparis P, Michelakis ED. Mitochondria in vascular health and disease. Annu Rev Physiol 75: 95–126, 2013. [DOI] [PubMed] [Google Scholar]
  • 24.Dromparis P, Paulin R, Sutendra G, Qi AC, Bonnet S, Michelakis ED. Uncoupling protein 2 deficiency mimics the effects of hypoxia and endoplasmic reticulum stress on mitochondria and triggers pseudohypoxic pulmonary vascular remodeling and pulmonary hypertension. Circ Res 113: 126–136, 2013. [DOI] [PubMed] [Google Scholar]
  • 25.Duffield JS, Lupher M, Thannickal VJ, Wynn TA. Host responses in tissue repair and fibrosis. Annu Rev Pathol 8: 241–276, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650–1659, 1986. [DOI] [PubMed] [Google Scholar]
  • 27.El Kasmi KC, Pugliese SC, Riddle SR, Poth JM, Anderson AL, Frid MG, Li M, Pullamsetti SS, Savai R, Nagel MA, Fini MA, Graham BB, Tuder RM, Friedman JE, Eltzschig HK, Sokol RJ, Stenmark KR. Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension. J Immunol 193: 597–609, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Everts B, Amiel E, Huang SC, Smith AM, Chang CH, Lam WY, Redmann V, Freitas TC, Blagih J, van der Windt GJ, Artyomov MN, Jones RG, Pearce EL, Pearce EJ. TLR-driven early glycolytic reprogramming via the kinases TBK1-IKKε supports the anabolic demands of dendritic cell activation. Nat Immunol 15: 323–332, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Everts B, Amiel E, van der Windt GJ, Freitas TC, Chott R, Yarasheski KE, Pearce EL, Pearce EJ. Commitment to glycolysis sustains survival of NO-producing inflammatory dendritic cells. Blood 120: 1422–1431, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 110: 20212–20217, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Fijalkowska I, Xu W, Comhair SA, Janocha AJ, Mavrakis LA, Krishnamachary B, Zhen L, Mao T, Richter A, Erzurum SC, Tuder RM. Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 176: 1130–1138, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Flavell SJ, Hou TZ, Lax S, Filer AD, Salmon M, Buckley CD. Fibroblasts as novel therapeutic targets in chronic inflammation. Br J Pharmacol 153, Suppl 1: S241–S246, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Freund-Michel V, Khoyrattee N, Savineau JP, Muller B, Guibert C. Mitochondria: roles in pulmonary hypertension. Int J Biochem Cell Biol 55: 93–97, 2014. [DOI] [PubMed] [Google Scholar]
  • 35.Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N, Stenmark KR. Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol 168: 659–669, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 31: 766–776, 2010. [DOI] [PubMed] [Google Scholar]
  • 37.Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 140: 883–899, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5: 253–295, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144: 646–674, 2011. [DOI] [PubMed] [Google Scholar]
  • 40.Hassoun PM, Mouthon L, Barbera JA, Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML, Michelakis ED, Morrell NW, Newman JH, Rabinovitch M, Schermuly R, Stenmark KR, Voelkel NF, Yuan JX, Humbert M. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 54: S10–S19, 2009. [DOI] [PubMed] [Google Scholar]
  • 41.Holt AP, Haughton EL, Lalor PF, Filer A, Buckley CD, Adams DH. Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver. Gastroenterology 136: 705–714, 2009. [DOI] [PubMed] [Google Scholar]
  • 42.Huang SC, Everts B, Ivanova Y, O'Sullivan D, Nascimento M, Smith AM, Beatty W, Love-Gregory L, Lam WY, O'Neill CM, Yan C, Du H, Abumrad NA, Urban JF Jr, Artyomov MN, Pearce EL, Pearce EJ. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nat Immunol 15: 846–855, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Iijima J, Konno K, Itano N. Inflammatory alterations of the extracellular matrix in the tumor microenvironment. Cancers (Basel) 3: 3189–3205, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Kaufman J, Graf BA, Leung EC, Pollock SJ, Koumas L, Reddy SY, Blieden TM, Smith TJ, Phipps RP. Fibroblasts as sentinel cells: role of the CDcd40-CDcd40 ligand system in fibroblast activation and lung inflammation and fibrosis. Chest 120: 53S–55S, 2001. [DOI] [PubMed] [Google Scholar]
  • 45.Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducolone A, Ehrhart M, Oswald-Mammosser M. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 164: 219–224, 2001. [DOI] [PubMed] [Google Scholar]
  • 46.Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer 11: 325–337, 2011. [DOI] [PubMed] [Google Scholar]
  • 47.Krawczyk CM, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis RJ, Cross JR, Jung E, Thompson CB, Jones RG, Pearce EJ. Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood 115: 4742–4749, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Kuang SQ, Geng L, Prakash SK, Cao JM, Guo S, Villamizar C, Kwartler CS, Peters AM, Brasier AR, Milewicz DM. Aortic remodeling after transverse aortic constriction in mice is attenuated with AT1 receptor blockade. Arterioscler Thromb Vasc Biol 33: 2172–2179, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Li M, Riddle SR, Frid MG, El Kasmi KC, McKinsey TA, Sokol RJ, Strassheim D, Meyrick B, Yeager ME, Flockton AR, McKeon BA, Lemon DD, Horn TR, Anwar A, Barajas C, Stenmark KR. Emergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertension. J Immunol 187: 2711–2722, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, Zha Z, Liu Y, Li Z, Xu Y, Wang G, Huang Y, Xiong Y, Guan KL, Lei QY. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. Mol Cell 42: 719–730, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, Fuchs JR, Eubank TD, Frankel WL, Bekaii-Saab T, Bloomston M, Lesinski GB. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 73: 3007–3018, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Makeyev EV, Zhang J, Carrasco MA, Maniatis T. The microRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing. Mol Cell 27: 435–448, 2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Maron BA, Choudhary G, Khan UA, Jankowich MD, McChesney H, Ferrazzani SJ, Gaddam S, Sharma S, Opotowsky AR, Bhatt DL, Rocco TP, Aragam JR. Clinical profile and underdiagnosis of pulmonary hypertension in US veteran patients. Circ Heart Fail 6: 906–912, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Marsboom G, Wietholt C, Haney CR, Toth PT, Ryan JJ, Morrow E, Thenappan T, Bache-Wiig P, Piao L, Paul J, Chen CT, Archer SL. Lung 18F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med 185: 670–679, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Martinez-Outschoorn UE, Lisanti MP, Sotgia F. Catabolic cancer-associated fibroblasts transfer energy and biomass to anabolic cancer cells, fueling tumor growth. Semin Cancer Biol 25: 47–60, 2014. [DOI] [PubMed] [Google Scholar]
  • 56.Metallo CM, Vander Heiden MG. Metabolism strikes back: metabolic flux regulates cell signaling. Genes Dev 24: 2717–2722, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, Lopaschuk GD, Puttagunta L, Waite R, Archer SL. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105: 244–250, 2002. [DOI] [PubMed] [Google Scholar]
  • 58.Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11: 723–737, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.O'Sullivan D, Pearce EL. Targeting T cell metabolism for therapy. Trends Immunol 36: 71–80, 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Odegaard JI, Chawla A. Alternative macrophage activation and metabolism. Annu Rev Pathol 6: 275–297, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Ohlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med 211: 1503–1523, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol 36: 229–239, 2015. [DOI] [PubMed] [Google Scholar]
  • 63.Otranto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 6: 203–219, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, van den Bosch MW, Quinn SR, Domingo-Fernandez R, Johnston DG, Jiang JK, Israelsen WJ, Keane J, Thomas C, Clish C, Vanden Heiden M, Xavier RJ, O'Neill LA. Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the Warburg effect in LPS-activated macrophages. Cell Metab 21: 65–80, 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Palsson-McDermott EM, O'Neill LA. The Warburg effect then and now: from cancer to inflammatory diseases. Bioessays 35: 965–973, 2013. [DOI] [PubMed] [Google Scholar]
  • 66.Panzhinskiy E, Zawada WM, Stenmark KR, Das M. Hypoxia induces unique proliferative response in adventitial fibroblasts by activating PDGFbeta receptor-JNK1 signalling. Cardiovasc Res 95: 356–365, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Paulin R, Michelakis ED. The metabolic theory of pulmonary arterial hypertension. Circ Res 115: 148–164, 2014. [DOI] [PubMed] [Google Scholar]
  • 68.Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 8: 3984–4001, 2009. [DOI] [PubMed] [Google Scholar]
  • 69.Pearce EJ, Everts B. Dendritic cell metabolism. Nat Rev Immunol 15: 18–29, 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM, Thompson RW, Cheever AW, Murray PJ, Wynn TA. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 5: e1000371, 2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Piao L, Marsboom G, Archer SL. Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl) 88: 1011–1020, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Psaltis PJ, Puranik AS, Spoon DB, Chue CD, Hoffman SJ, Witt TA, Delacroix S, Kleppe LS, Mueske CS, Pan S, Gulati R, Simari RD. Characterization of a resident population of adventitial macrophage progenitor cells in postnatal vasculature. Circ Res 115: 364–375, 2014. [DOI] [PubMed] [Google Scholar]
  • 73.Pugliese SC, Poth JM, Fini MA, Olschewski A, El Kasmi KC, Stenmark KR. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol 308: L229–L252, 2015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Qualls JE, Subramanian C, Rafi W, Smith AM, Balouzian L, DeFreitas AA, Shirey KA, Reutterer B, Kernbauer E, Stockinger S, Decker T, Miyairi I, Vogel SN, Salgame P, Rock CO, Murray PJ. Sustained generation of nitric oxide and control of mycobacterial infection requires argininosuccinate synthase 1. Cell Host Microbe 12: 313–323, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75.Rasanen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res 316: 2713–2722, 2010. [DOI] [PubMed] [Google Scholar]
  • 76.Rodriguez-Prados JC, Traves PG, Cuenca J, Rico D, Aragones J, Martin-Sanz P, Cascante M, Bosca L. Substrate fate in activated macrophages: a comparison between innate, classic, and alternative activation. J Immunol 185: 605–614, 2010. [DOI] [PubMed] [Google Scholar]
  • 77.Savai R, Pullamsetti SS, Kolbe J, Bieniek E, Voswinckel R, Fink L, Scheed A, Ritter C, Dahal BK, Vater A, Klussmann S, Ghofrani HA, Weissmann N, Klepetko W, Banat GA, Seeger W, Grimminger F, Schermuly RT. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 186: 897–908, 2012. [DOI] [PubMed] [Google Scholar]
  • 78.Seeger W, Adir Y, Barbera JA, Champion H, Coghlan JG, Cottin V, De Marco T, Galie N, Ghio S, Gibbs S, Martinez FJ, Semigran MJ, Simonneau G, Wells AU, Vachiery JL. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 62: D109–D116, 2013. [DOI] [PubMed] [Google Scholar]
  • 79.Servais C, Erez N. From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol 229: 198–207, 2013. [DOI] [PubMed] [Google Scholar]
  • 80.Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 62: D34–D41, 2013. [DOI] [PubMed] [Google Scholar]
  • 81.Sivakumar P, Ntolios P, Jenkins G, Laurent G. Into the matrix: targeting fibroblasts in pulmonary fibrosis. Curr Opin Pulm Med 18: 462–469, 2012. [DOI] [PubMed] [Google Scholar]
  • 82.Smith RS, Smith TJ, Blieden TM, Phipps RP. Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol 151: 317–322, 1997. [PMC free article] [PubMed] [Google Scholar]
  • 83.Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99: 675–691, 2006. [DOI] [PubMed] [Google Scholar]
  • 84.Stenmark KR, Frid MG, Yeager M, Li M, Riddle S, McKinsey T, El Kasmi KC. Targeting the adventitial microenvironment in pulmonary hypertension: a potential approach to therapy that considers epigenetic change. Pulm Circ 2: 3–14, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Stenmark KR, Meyrick B, Galie N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 297: L1013–L1032, 2009. [DOI] [PubMed] [Google Scholar]
  • 86.Stenmark KR, Nozik-Grayck E, Gerasimovskaya E, Anwar A, Li M, Riddle S, Frid M. The adventitia: essential role in pulmonary vascular remodeling. Compr Physiol 1: 141–161, 2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 87.Stenmark KR, Yeager ME, El Kasmi KC, Nozik-Grayck E, Gerasimovskaya EV, Li M, Riddle SR, Frid MG. The adventitia: essential regulator of vascular wall structure and function. Annu Rev Physiol 75: 23–47, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Sutendra G, Bonnet S, Rochefort G, Haromy A, Folmes KD, Lopaschuk GD, Dyck JR, Michelakis ED. Fatty acid oxidation and malonyl-CoA decarboxylase in the vascular remodeling of pulmonary hypertension. Sci Transl Med 2: 44ra58, 2010. [DOI] [PubMed] [Google Scholar]
  • 89.Tang PC, Qin L, Zielonka J, Zhou J, Matte-Martone C, Bergaya S, van Rooijen N, Shlomchik WD, Min W, Sessa WC, Pober JS, Tellides G. MyD88-dependent, superoxide-initiated inflammation is necessary for flow-mediated inward remodeling of conduit arteries. J Exp Med 205: 3159–3171, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Tannahill GM, Curtis AM, Adamik J, Palsson-McDermott EM, McGettrick AF, Goel G, Frezza C, Bernard NJ, Kelly B, Foley NH, Zheng L, Gardet A, Tong Z, Jany SS, Corr SC, Haneklaus M, Caffrey BE, Pierce K, Walmsley S, Beasley FC, Cummins E, Nizet V, Whyte M, Taylor CT, Lin H, Masters SL, Gottlieb E, Kelly VP, Clish C, Auron PE, Xavier RJ, O'Neill LA. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 496: 238–242, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91.Tellides G, Pober JS. Inflammatory and immune responses in the arterial media. Circ Res 116: 312–322, 2015. [DOI] [PubMed] [Google Scholar]
  • 92.Torres S, Bartolome RA, Mendes M, Barderas R, Fernandez-Acenero MJ, Pelaez-Garcia A, Pena C, Lopez-Lucendo M, Villar-Vazquez R, de Herreros AG, Bonilla F, Casal JI. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res 19: 6006–6019, 2013. [DOI] [PubMed] [Google Scholar]
  • 93.Tuder RM, Archer SL, Dorfmuller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62: D4–D12, 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95.Tuder RM, Davis LA, Graham BB. Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 185: 260–266, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 96.van Nieuwenhoven FA, Turner NA. The role of cardiac fibroblasts in the transition from inflammation to fibrosis following myocardial infarction. Vascul Pharmacol 58: 182–188, 2013. [DOI] [PubMed] [Google Scholar]
  • 97.Vats D, Mukundan L, Odegaard JI, Zhang L, Smith KL, Morel CR, Wagner RA, Greaves DR, Murray PJ, Chawla A. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab 4: 13–24, 2006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 98.Wang D, Zhang H, Li M, Frid MG, Flockton AR, McKeon BA, Yeager ME, Fini MA, Morrell NW, Pullamsetti SS, Velegala S, Seeger W, McKinsey TA, Sucharov CC, Stenmark KR. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. Circ Res 114: 67–78, 2014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Wang J, Ying G, Wang J, Jung Y, Lu J, Zhu J, Pienta KJ, Taichman RS. Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res 70: 471–480, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 100.Wang P, Chen L, Zhang J, Chen H, Fan J, Wang K, Luo J, Chen Z, Meng Z, Liu L. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 33: 514–524, 2014. [DOI] [PubMed] [Google Scholar]
  • 101.Wellen KE, Thompson CB. A two-way street: reciprocal regulation of metabolism and signalling. Nat Rev Mol Cell Biol 13: 270–276, 2012. [DOI] [PubMed] [Google Scholar]
  • 102.Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199–210, 2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 103.Yang P, Li Z, Fu R, Wu H, Li Z. Pyruvate kinase M2 facilitates colon cancer cell migration via the modulation of STAT3 signalling. Cell Signal 26: 1853–1862, 2014. [DOI] [PubMed] [Google Scholar]
  • 104.Yang P, Li Z, Li H, Lu Y, Wu H, Li Z. Pyruvate kinase M2 accelerates pro-inflammatory cytokine secretion and cell proliferation induced by lipopolysaccharide in colorectal cancer. Cell Signal 27: 1525–1532, 2015. [DOI] [PubMed] [Google Scholar]
  • 105.Zhao L, Ashek A, Wang L, Fang W, Dabral S, Dubois O, Cupitt J, Pullamsetti SS, Cotroneo E, Jones H, Tomasi G, Nguyen QD, Aboagye EO, El-Bahrawy MA, Barnes G, Howard LS, Gibbs JS, Gsell W, He JG, Wilkins MR. Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments. Circulation 128: 1214–1224, 2013. [DOI] [PubMed] [Google Scholar]
  • 106.Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126: 455–467, 2012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107.Zhao S, Xu W, Jiang W, Yu W, Lin Y, Zhang T, Yao J, Zhou L, Zeng Y, Li H, Li Y, Shi J, An W, Hancock SM, He F, Qin L, Chin J, Yang P, Chen X, Lei Q, Xiong Y, Guan KL. Regulation of cellular metabolism by protein lysine acetylation. Science 327: 1000–1004, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108.Zhou J, Tang PC, Qin L, Gayed PM, Li W, Skokos EA, Kyriakides TR, Pober JS, Tellides G. CXCR3-dependent accumulation and activation of perivascular macrophages is necessary for homeostatic arterial remodeling to hemodynamic stresses. J Exp Med 207: 1951–1966, 2010. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Applied Physiology are provided here courtesy of American Physiological Society

RESOURCES